Insider Transactions Reported by 23 Insiders of Blueprint Medicines Corp

Location
Cambridge, MA

Insiders trading volume in the past year

Blueprint Medicines Corp executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Jeffrey W. Albers Director $9,327,825 -$505,692 -5.1% 17 Jul 2025
Nicholas Lydon Director $6,168,869 12 Jun 2024
Christopher K. Murray Chief Technical Operations $3,445,379 07 Mar 2024
Kate Haviland Chief Executive Officer, Director $2,537,920 -$216,461 -7.9% 17 Jul 2025
Philina Lee Chief Commercial Officer $2,104,740 17 Jul 2025
Christina Rossi Chief Operating Officer $951,720 -$826,328 -46% 17 Jul 2025
Fouad Namouni President, R & D $951,720 17 Jul 2025
George Demetri Director $836,633 21 Jun 2022
Michael Landsittel Chief Financial Officer $793,100 17 Jul 2025
Tracey L. McCain EVP & Chief Legal Officer $793,100 17 Jul 2025
Debra Durso-Bumpus Chief People Officer $793,100 17 Jul 2025
Percy H. Carter Chief Scientific Officer $793,100 -$474,824 -37% 17 Jul 2025
Ariel Hurley Principal Accounting Officer $670,360 -$283,819 -30% 17 Jul 2025
Charles A. Rowland Jr Director $590,625 02 Jun 2021
Tango Therapeutics, Inc. Director $411,070 08 Dec 2021
L. Becker Hewes Chief Medical Officer $289,258 17 Jul 2025
LONNEL COATS Director $47,852 17 Jul 2025
Alexis Borisy Director $0 17 Jul 2025
Habib J. Dable Director $0 17 Jul 2025
Daniella Beckman Director $0 17 Jul 2025
Mark Alan Goldberg Director $0 17 Jul 2025
Lynn Seely Director $0 17 Jul 2025
John Tsai Director $0 17 Jul 2025

Recent Insider Transactions by Companies or Individuals for Blueprint Medicines Corp

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.